Does Horizon Blue Cross Blue Shield of New Jersey Cover Cialis?

How Horizon BCBSNJ Formularies Handle Cialis and Tadalafil

Horizon Blue Cross Blue Shield of New Jersey uses a tiered formulary system across its commercial, Medicare Advantage, and ACA marketplace plans. Brand-name Cialis sits on Tier 3 or Tier 4 in most Horizon commercial formularies, while FDA-approved generic tadalafil typically lands on Tier 2. That distinction matters enormously at the pharmacy counter.

Brand Cialis vs. Generic Tadalafil: The Tier Difference

The FDA approved the first generic tadalafil tablets in September 2018, opening the door to dramatically lower out-of-pocket costs for patients [1]. Before that approval, brand Cialis held exclusivity and commanded prices exceeding $400 per month without insurance. Generic tadalafil from manufacturers such as Lilly (authorized generic) and multiple ANDA-approved competitors now retails for $30, $80 per month at many NJ pharmacies.

Horizon's standard commercial formulary lists generic tadalafil at Tier 2 with a copay that typically falls between $40 and $75 for a 30-day supply after the deductible is met. Brand Cialis, if listed at all, may appear on a non-preferred Tier 3 or specialty Tier 4 with cost-sharing exceeding $100, $200 per fill.

What the Diagnosis Code on Your Prescription Means

Coverage decisions often hinge on whether the claim is submitted under an erectile dysfunction diagnosis (ICD-10 N52.x) or a benign prostatic hyperplasia diagnosis (ICD-10 N40.x). Some Horizon plans explicitly exclude medications prescribed solely for sexual dysfunction, while the same drug prescribed for BPH-related urinary symptoms may be covered under a medical benefit rather than a pharmacy benefit. Tadalafil 5 mg once daily is FDA-approved for both BPH and ED [2], so the indication on the prescription directly shapes the reimbursement outcome.

Medicare Advantage Plans Through Horizon

Medicare Part D has historically excluded coverage of drugs used "for the treatment of sexual or erectile dysfunction" unless those drugs are used for a different, covered indication [3]. Horizon Medicare Advantage members should ask their physician to document any concurrent BPH or pulmonary arterial hypertension diagnosis if applicable, since those indications do not fall under the Part D exclusion. Adcirca (tadalafil 20 mg for pulmonary arterial hypertension) is covered under different rules entirely and should not be confused with Cialis dosing for ED.

Clinical Evidence Supporting Tadalafil for Erectile Dysfunction

Understanding why a drug warrants coverage requires looking at the evidence behind it. Tadalafil has an extensive body of Phase III data supporting its efficacy in ED, which physicians can cite when writing prior authorization letters.

IIEF Scores and Key Trial Results

The International Index of Erectile Function (IIEF) is the validated 15-item questionnaire used in most ED clinical trials [4]. In the key placebo-controlled registration trial for tadalafil 20 mg on-demand, the IIEF Erectile Function domain score improved by a mean of 7.3 points from baseline versus 1.5 points for placebo (P<0.001) [5]. Successful intercourse rates reached 75% in the tadalafil arm compared with 32% in the placebo arm [5].

Once-Daily Dosing Evidence

Tadalafil 5 mg once daily was evaluated in a 12-week randomized trial (N=268) that showed statistically significant improvement in IIEF-EF scores compared with placebo, with a mean difference of 5.1 points (P<0.001) [6]. This once-daily regimen is particularly relevant for coverage arguments because it aligns with standard chronic-disease management. Insurers are more accustomed to authorizing maintenance medications taken daily than on-demand drugs, and physicians can frame tadalafil 5 mg in that context.

Cardiovascular Safety Considerations

The FDA label for tadalafil carries a contraindication with nitrate medications due to risk of severe hypotension [2]. The Princeton Consensus Panel guidelines, last updated in their third iteration, recommend that clinicians assess cardiovascular risk before prescribing any PDE5 inhibitor, using a structured framework that stratifies patients into low, intermediate, and high risk [7]. Patients on stable cardiac regimens who are classified as low risk may safely use tadalafil, and documenting this assessment in the chart strengthens a prior authorization submission.

Prior Authorization for Cialis and Tadalafil Under Horizon Plans

Prior authorization (PA) is the single largest barrier to coverage approval for tadalafil under Horizon BCBSNJ plans. Knowing the specific requirements in advance shortens the approval timeline significantly.

What Horizon Typically Requires in a PA Request

Most Horizon commercial plan PA criteria for tadalafil include:

• A documented diagnosis of ED or BPH confirmed by a licensed prescriber
• Patient age (most plans restrict coverage to adults 18 years and older)
• Confirmation that the prescriber has evaluated cardiovascular contraindications
• Quantity limits (commonly 4 to 8 tablets per 30 days for on-demand dosing, or 30 tablets per 30 days for once-daily 5 mg)
• Step therapy documentation showing that a less-expensive PDE5 inhibitor (sildenafil) was tried or is contraindicated

Horizon publishes its medical and pharmacy policies on its provider portal. The specific PA form for PDE5 inhibitors falls under the pharmacy benefit management (PBM) tier, and as of 2024, Horizon's PBM partner administers these requests through an online submission system accessible to in-network prescribers.

Step Therapy: The Sildenafil-First Requirement

Step therapy means the insurer requires a trial of a preferred, lower-cost drug before authorizing the requested medication. For Horizon members seeking tadalafil, sildenafil (generic Viagra) is commonly the required first step. Sildenafil generic has been available since 2017 and retails for as little as $10, $30 per month, which is why plans push it as the default PDE5 inhibitor.

If a patient cannot tolerate sildenafil due to visual disturbances, severe facial flushing, or its shorter 4 to 6-hour window of action, that intolerance should be documented in the medical record and included in the PA letter. New Jersey's Patients First Act (effective 2020) provides some step therapy override protections, giving patients the right to request a clinical exception if step therapy is contraindicated or has been ineffective [see NJ P.L. 2019, c. 278].

What to Do After a PA Denial

A denial is not final. Horizon members have the right to:

1. Request an internal appeal within 180 days of the denial notice
2. Request an expedited internal appeal (72-hour decision) if the condition is urgent
3. File an external appeal with the NJ Department of Banking and Insurance (DOBI) if the internal appeal is denied
4. Request a peer-to-peer review between the prescribing physician and the Horizon medical director

The prescribing physician's letter for appeal should cite the specific clinical trial data supporting tadalafil's superiority over sildenafil for the individual patient, reference the IIEF scoring, and note any comorbidities (BPH, diabetes-related ED, post-prostatectomy ED) that justify the choice.

Tadalafil for BPH: A Separate and Often Overlooked Coverage Pathway

Many Horizon members and even some prescribers overlook the fact that tadalafil 5 mg is FDA-approved for the signs and symptoms of benign prostatic hyperplasia [2]. This creates a distinct coverage pathway that bypasses some ED-specific exclusions.

Clinical Evidence for BPH Indication

A meta-analysis of randomized controlled trials published in the European Urology journal (PMID 22459044) pooled data from four 12-week trials (N=1,058 total) and found that tadalafil 5 mg once daily produced a statistically significant improvement in International Prostate Symptom Score (IPSS) of 3.8 points versus 1.7 points for placebo (P<0.001) [8]. That magnitude of improvement is clinically meaningful and comparable to alpha-blocker monotherapy in mild-to-moderate BPH.

How to Frame the BPH Claim for Horizon

When a patient has documented BPH alongside ED, the prescribing physician should submit the PA request with ICD-10 code N40.1 (BPH with lower urinary tract symptoms) as the primary diagnosis. The pharmacy claim submitted under a BPH indication avoids the sexual dysfunction exclusion that appears in some Horizon plan documents. This is a fully legitimate clinical and billing practice, not a workaround, because the FDA label explicitly supports both indications.

What Horizon Plans Typically Exclude and Why

Not every Horizon plan covers medications for sexual dysfunction. Employer-sponsored self-funded plans (governed by ERISA rather than NJ state insurance law) can exclude sexual dysfunction drugs entirely, and Horizon administers many such plans for NJ employers. State insurance mandates do not apply to ERISA plans.

Checking Your Specific Plan Document

The Summary Plan Description (SPD) or Evidence of Coverage (EOC) document for your specific plan is the controlling legal document. Phrases to search for include "sexual dysfunction," "erectile dysfunction," "PDE5 inhibitor," and "lifestyle drugs." If those terms appear in an exclusion list, coverage is unlikely regardless of the diagnosis code submitted.

Horizon's member portal at member.horizonblue.com allows members to search the formulary by drug name and view cost-sharing tiers. The formulary search tool is updated periodically, and a drug's tier can change mid-year during formulary updates. Checking the formulary at the point of prescribing and again at the pharmacy is advisable.

ACA Marketplace Plan Rules

ACA plans sold on Get Covered NJ are required to comply with NJ state insurance mandates, but coverage of ED medications is not currently a mandated benefit in New Jersey. Horizon's ACA Silver and Gold plans vary in whether they include tadalafil on formulary. Some Silver plans list generic tadalafil with a $50 copay after deductible; others exclude it entirely.

Original Clinical Decision Framework for Pursuing Tadalafil Coverage Through Horizon

The following three-step framework is used by HealthRX clinicians when prescribing tadalafil to Horizon BCBSNJ members. It is designed to maximize the probability of coverage approval at the first submission.

Step 1: Identify the strongest supported diagnosis. Document ED, BPH, or both in the clinical note using ICD-10 specificity (e.g., N52.9 for unspecified ED; N40.1 for BPH with LUTS). If BPH is present, list it as primary.

Step 2: Choose the formulation aligned with daily chronic-disease framing. Tadalafil 5 mg once daily is more likely to pass utilization review than tadalafil 20 mg on-demand, because daily dosing aligns with how plans manage chronic conditions. The FDA label supports this dose for both BPH and ED [2].

Step 3: Pre-empt step therapy by documenting sildenafil intolerance or failure. If the patient has not tried sildenafil, consider a brief trial and document outcomes. If the patient cannot use sildenafil (nitrate use, NAION history, color-vision defect, or timing incompatibility with sexual activity), document this explicitly before submitting the PA, citing the FDA label contraindications [2] and the Princeton Consensus cardiovascular stratification [7].

Cost Comparison: Covered vs. Out-of-Pocket Tadalafil in New Jersey

For patients whose Horizon plan does not cover tadalafil, out-of-pocket options have become substantially more affordable since generic entry in 2018 [1].

| Option | Approximate Monthly Cost (NJ, 2025) | |---|---| | Brand Cialis 20 mg x 8 tablets (no insurance) | $420, $510 | | Generic tadalafil 20 mg x 8 tablets (GoodRx/cash) | $25, $55 | | Generic tadalafil 5 mg x 30 tablets (GoodRx/cash) | $30, $70 | | Horizon Tier 2 copay (generic, post-deductible) | $40, $75 | | Horizon Tier 3 copay (brand, post-deductible) | $100, $200+ |

These figures reflect 2025 pricing at major NJ pharmacy chains. GoodRx and similar discount programs function as an alternative to insurance for generic tadalafil and may produce a lower out-of-pocket cost than the Horizon copay for patients who have not met their deductible.

How a Telehealth Prescriber Can Help With Horizon Coverage

Board-certified physicians writing tadalafil prescriptions through HealthRX are trained in PA submission for NJ-based insurers, including Horizon BCBSNJ. A well-constructed PA letter citing trial-level evidence significantly improves approval rates compared to a pharmacy-generated auto-request.

The American Urological Association (AUA) 2018 guideline on erectile dysfunction states: "Phosphodiesterase type 5 inhibitors (PDE5i) are recommended as first-line therapy for the treatment of erectile dysfunction in the appropriate patient population" [9]. That guideline language gives prescribers a direct citation to use in PA letters and appeal submissions.

The Endocrine Society's clinical practice guideline on male hypogonadism notes that when ED is a symptom of an underlying hormonal disorder, treating the primary condition (e.g., low testosterone) may improve ED, but PDE5 inhibitors remain an effective adjunct therapy [10]. For patients with documented hypogonadism on Horizon's plan, a dual diagnosis (hypogonadism plus ED) can support both testosterone therapy and tadalafil coverage.

The FDA drug label for tadalafil (NDA 021368) lists the approved indications, contraindications, and dosing schedules that form the basis of any coverage or PA argument [2]. Prescribers should reference this label directly in prior authorization correspondence.

When Tadalafil Is Not Appropriate: Safety and Contraindications

Coverage is irrelevant if the drug is medically contraindicated. Tadalafil is contraindicated in patients using any form of organic nitrate (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) because the combination produces unpredictable and potentially severe hypotension [2]. It is also contraindicated in patients with severe hepatic impairment (Child-Pugh Class C) and those with prior non-arteritic anterior ischemic optic neuropathy (NAION).

Patients with chronic kidney disease (creatinine clearance <30 mL/min) require dose adjustment. The FDA label specifies that for CrCl <30 mL/min, once-daily dosing of tadalafil is not recommended, and on-demand dosing should not exceed 5 mg per 72 hours [2].

A 2014 cohort study (N=11,327) published in JAMA Internal Medicine found no significant increase in acute myocardial infarction risk associated with PDE5 inhibitor use in men with stable cardiovascular disease who were appropriately screened [11]. That finding supports prescribing in low-risk cardiac patients when properly evaluated.

Practical Steps to Verify Your Horizon Coverage Today

1. Call the member services number on the back of your Horizon ID card and ask specifically: "Is tadalafil covered under my pharmacy benefit? What tier is it? Is prior authorization required?"
2. Log into member.horizonblue.com, manage to "Pharmacy," and run a formulary search for "tadalafil."
3. Ask your prescribing physician to check the Horizon provider portal for current PA criteria before submitting a prescription.
4. If your plan is employer-sponsored, request a copy of the Summary Plan Description from your HR department and search it for exclusions.
5. If denied, request the written denial letter, which must state the specific reason and the appeals procedure under federal and NJ law.